
浏览全部资源
扫码关注微信
1.郑州大学第三附属医院生殖中心,郑州 450052
2.河南中医药大学豫药全产业链研发河南省协同创新中心,郑州 450046
主治医师,博士。研究方向:中医药治疗生殖内分泌疾病。E-mail:liqiufang0811@126.com
副教授,硕士生导师,博士。研究方向:中药资源综合开发与中药物质基础。E-mail:liuyalin@hactcm.edu.cn
收稿:2026-06-08,
修回:2026-10-14,
录用:2026-10-15,
纸质出版:2026-10-30
移动端阅览
李秋芳,李少玉,龚曼,等.黄连-麦冬药对对2型糖尿病大鼠的改善作用及机制研究 [J].中国药房,2026,37(20):2685-2692.
LI Qiufang,LI Shaoyu,GONG Man,et al.Study on the ameliorative effects and mechanisms of Coptidis Rhizoma-Ophiopogonis Radix herb pair in rats with type 2 diabetes mellitus[J].ZHONGGUO YAOFANG,2026,37(20):2685-2692.
李秋芳,李少玉,龚曼,等.黄连-麦冬药对对2型糖尿病大鼠的改善作用及机制研究 [J].中国药房,2026,37(20):2685-2692. DOI: 10.6039/j.issn.1001-0408.2026.20.10.
LI Qiufang,LI Shaoyu,GONG Man,et al.Study on the ameliorative effects and mechanisms of Coptidis Rhizoma-Ophiopogonis Radix herb pair in rats with type 2 diabetes mellitus[J].ZHONGGUO YAOFANG,2026,37(20):2685-2692. DOI: 10.6039/j.issn.1001-0408.2026.20.10.
目的
2
探讨黄连-麦冬药对(HLMD)对2型糖尿病(T2DM)大鼠的改善作用及潜在机制。
方法
2
将雄性Wistar大鼠分为正常组(6只)和造模组(30只)。造模组大鼠以高糖高脂饲料喂养联合链脲佐菌素腹腔注射的方式构建T2DM模型,并将造模成功的大鼠分为模型组、二甲双胍组(200 mg/kg)和HLMD低、中、高剂量组(100、200、400 mg/kg),每组6只。各组大鼠灌胃相应药液或生理盐水,每天1次,连续6周。检测各组大鼠体重、空腹血糖(FBG)、口服葡萄糖耐量实验曲线下面积(AUC)和血脂指标[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、炎症因子[白细胞介素6(IL-6)、IL-1β、肿瘤坏死因子α(TNF-α)、IL-10]水平,观察肝脏、胰腺组织的病理形态学以及肝脏组织的脂质沉积情况,分析正常组、模型组、HLMD高剂量组大鼠的肠道菌群变化情况;借助网络药理学和分子对接分析HLMD改善T2DM的潜在靶点并验证。
结果
2
与模型组比较,HLMD各剂量组大鼠体重普遍回升,FBG持续下降;胰岛形态紊乱、肝细胞排列紊乱、肝索坏死、脂质沉积等病理改变均有不同程度改善;AUC(低剂量组除外),TC、TG、LDL-C、IL-6(低剂量组除外)、IL-1β、TNF-α水平,Simpson和Shannon指数,厚壁菌门、变形菌门和梭菌属的相对丰度均显著降低;HDL-C(低剂量组除外)、IL-10(低剂量组除外)水平,拟杆菌门和联合乳杆菌属的相对丰度均显著升高(
P
<0.05)。网络药理学和分子对接预测结果显示,HLMD活性成分(槲皮素、腺苷、齐墩果酸、豆甾醇、麦冬皂苷D′等)可通过靶向蛋白激酶B1(Akt1)、TNF、IL-6、P53、IL-1β等关键靶点来改善T2DM。验证结果显示,HLMD可显著下调T2DM大鼠肝组织中P53(低剂量组除外)、IL-6(低剂量组除外)、IL-1β、TNF-α蛋白的表达(
P
<0.05)。
结论
2
HLMD可改善T2DM大鼠的糖脂代谢紊乱,减轻炎症反应及肝脏、胰腺组织的病理损伤;上述作用可能与该药对调节肠道菌群组成及下调P53、IL-6、IL-1β、TNF-α等炎症相关靶点的表达有关。
OBJECTIVE
2
To investigate the ameliorative effects of Coptidis Rhizoma-Ophiopogonis Radix herb pair (HLMD) in rats with type 2 diabetes mellitus (T2DM) and its potential mechanisms.
METHODS
2
Male Wistar rats were randomly divided into a control group (6 rats) and a model induction group (30 rats). The T2DM rat model was established by feeding a high-sugar and high-fat diet combined with intraperitoneal injection of streptozotocin. The successfully modeled rats were subsequently divided into the model group, the metformin group (200 mg/kg), and the low-, medium-, and high-dose HLMD groups (100, 200 and 400 mg/kg, respectively), with six rats in each group. Rats in each group were administered the corresponding drug solution or normal saline by oral gavage once daily for six consecutive weeks. Body weight, fasting blood glucose (FBG), the area under the curve (AUC) of the oral glucose tolerance test, serum lipid profiles [total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)], and inflammatory cytokine [interleukin-6 (IL-6), IL-1β, tumor necrosis factor-α (TNF-α), and IL-10] levels were measured. Histopathological changes in liver and pancreatic tissues, as well as hepatic lipid accumulation, were evaluated. Changes in gut microbiota composition were analyzed in the control, model, and high-dose HLMD groups. Network pharmacology and molecular docking analyses were performed to identify potential therapeutic targets of HLMD against T2DM, followed by experimental validation.
RESULTS
2
Compared with the model group, the body weight generally recovered in rats in all HLMD dose groups, while FBG levels consistently decreased. Histopathological abnormalities, including disrupted pancreatic islet architecture, disorganized hepatocyte
arrangement, hepatic cord necrosis, and lipid accumulation, were alleviated to varying degrees. AUC (except for the low-dose group), levels of TC, TG, LDL-C, IL-6(except for the low-dose group), IL-1β and TNF-α, Simpson and Shannon indices, as well as the relative abundances of Firmicutes, Proteobacteria, and
Clostridium
were significantly reduced; meanwhile, the levels of HDL-C(except for the low-dose group) and IL-10 (except for the low-dose group), as well as the relative abundances of Bacteroidota and
Ligilactobacillus
were significantly increased (
P
<0.05). Network pharmacology and molecular docking analyses suggested that the active constituents of HLMD, including quercetin, adenosine, oleanolic acid, stigmasterol, and ophiopogonin D′, may exert antidiabetic effects by targeting key proteins such as protein kinase B1(Akt1), TNF, IL-6, P53 and IL-1β. Experimental validation further demonstrated that HLMD significantly downregulated the protein expressions of P53 (except for the low-dose group), IL-6 (except for the low-dose group), IL-1β and TNF-α in the liver tissues of T2DM rats (
P
<0.05).
CONCLUSIONS
2
HLMD alleviates glucose and lipid metabolism disorders, attenuates inflammatory responses, and ameliorates hepatic and pancreatic tissue damage in T2DM rats. These beneficial effects may be associated with the modulation of gut microbiota composition and the downregulation of inflammation-related targets, including P53, IL-6, IL-1β and TNF-α.
Hafezi S G , Saberi-Karimian M , Ghasemi M , et al . Prediction of the 10-year incidence of type 2 diabetes mellitus based on advanced anthropometric indices using machine learning methods in the Iranian population [J ] . Diabetes Res Clin Pract , 2024 , 214 : 111755 .
Tanase D M , Gosav E M , Neculae E , et al . Role of gut microbiota on onset and progression of microvascular complications of type 2 diabetes (T2DM) [J ] . Nutrients , 2020 , 12 ( 12 ): 3719 .
傅乐斌 , 时程遥 , 徐佳玲 , 等 . 2型糖尿病从气耗阴伤论治的研究概况 [J ] . 江西中医药 , 2025 , 56 ( 5 ): 61 - 66 .
Zhang W L , Chen W Y , Lei J W , et al . The expression of MAFB gene in circulating monocytes is related to chronic inflammatory status in T2DM patients [J ] . Inflammation , 2024 , 47 ( 5 ): 1837 - 1852 .
Chen S , Jiao Y Q , Han Y Y , et al . Edible traditional Chinese medicines improve type 2 diabetes by modulating gut microbiotal metabolites [J ] . Acta Diabetol , 2024 , 61 ( 4 ): 393 - 411 .
Qiao Y H , Jiao H Y , Wang F , et al . Ophiopogonin D of Ophiopogon japonicus ameliorates renal function by suppressing oxidative stress and inflammatory response in streptozotocin-induced diabetic nephropathy rats [J ] . Braz J Med Biol Res , 2020 , 53 ( 7 ): e9628 .
席啸虎 , 高建平 , 王世伟 , 等 . 麦冬-黄连药对 “异病同治” 溃疡性结肠炎和糖尿病的网络药理学分析及活性验证 [J ] . 中国医院药学杂志 , 2026 , 46 ( 6 ): 655 - 663,697 .
Ge Y F , Zhang Y Z , Liu S , et al . TCM-based natural pro-ducts in type 2 diabetes:a comprehensive review of bio-active compounds and molecular mechanisms [J ] . Mol Di-vers , 2026 , 30 ( 5 ): 7795 - 7809 .
李少玉 , 龚曼 , 李秋芳 , 等 . 基于EGFR/PI3K/Akt信号通路探讨黄连-麦冬药对延缓糖尿病肾病的作用机制 [J ] . 中国实验方剂学杂志 , 2024 , 30 ( 20 ): 22 - 29 .
Du Y H , Neng Q L , Li Y , et al . Gastrointestinal autonomic neuropathy exacerbates gut microbiota dysbiosis in adult patients with type 2 diabetes mellitus [J ] . Front Cell Infect Microbiol , 2021 , 11 : 804733 .
郭春风 , 蒋鑫 , 程汝阳 , 等 . 基于网络药理学和代谢组学的蟾宝痔疮栓抗痔疮的机制研究 [J ] . 中国药房 , 2025 , 36 ( 13 ): 1622 - 1628 .
Singh S B , Carroll-Portillo A , Lin H C . Desulfovibrio in the gut:the enemy within [J ] . Microorganisms , 2023 , 11 ( 7 ): 1772 .
Hubacek J A , Dlouha L , Adamkova V , et al . Genetic risk score is associated with T2DM and diabetes complications risks [J ] . Gene , 2023 , 849 : 146921 .
陈源 , 李振华 , 岳仁宋 , 等 . 黄连大黄药对调控ROS/NF-κB/GSDMD信号通路对2型糖尿病大鼠胰岛β细胞焦亡的影响 [J ] . 中华中医药学刊 , 2024 , 42 ( 11 ): 61 - 66 , 61 - 66, 后插19,后插20.
Chen K Q , Wang S Z , Lei H B , et al . Ophiopogonin D:review of pharmacological activity [J ] . Front Pharmacol , 2024 , 15 : 1401627 .
Cheung S G , Goldenthal A R , Uhlemann A C , et al . Systematic review of gut microbiota and major depression [J ] . Front Psychiatry , 2019 , 10 : 34 .
Huang Y S , Gong Z M , Yan C , et al . Investigation on the mechanisms of Zanthoxylum bungeanum for treating diabetes mellitus based on network pharmacology,molecular docking,and experiment verification [J ] . Biomed Res Int , 2023 , 2023 : 9298728 .
Taşkıran E , Erbaş O , Yiğittürk G , et al . Exogenously administered adenosine attenuates renal damage in streptozotocin-induced diabetic rats [J ] . Ren Fail , 2016 , 38 ( 8 ): 1276 - 1282 .
An Q , Hu Q , Wang B , et al . Oleanolic acid alleviates diabetic rat carotid artery injury through the inhibition of NLRP3 inflammasome signaling pathways [J ] . Mol Med Rep , 2017 , 16 ( 6 ): 8413 - 8419 .
Kishore L , Kaur N , Singh R . Renoprotective effect of Bacopa monnieri via inhibition of advanced glycation end products and oxidative stress in STZ-nicotinamide-induced diabetic nephropathy [J ] . Ren Fail , 2016 , 38 ( 9 ): 1528 - 1544 .
徐焕华 , 江珍红 , 姚泓 , 等 . 基于药物相互作用研究麦冬皂苷D对麦冬皂苷D′急性和亚急性毒性的影响 [J ] . 中国药理学与毒理学杂志 , 2022 , 36 ( 5 ): 370 - 377 .
Luo W F , Deng J , He J C , et al . Integration of molecular docking,molecular dynamics and network pharmacology to explore the multi-target pharmacology of fenugreek against diabetes [J ] . J Cell Mol Med , 2023 , 27 ( 14 ): 1959 - 1974 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621